Emicizumab is a monoclonal antibody used to prevent bleeding episodes in individuals with hemophilia A. It mimics the function of factor VIII, promoting effective clot formation. Emicizumab is crucial for managing bleeding disorders in hemophilia patients. In summary, it significantly reduces the risk of bleeding.
Emicizumab bridges activated factor IX and factor X, facilitating thrombin generation and promoting hemostasis.
No published brands for this salt yet.